Ireland is home to the world’s top pharma companies
Chanelle Pharma is Ireland’s largest indigenous manufacturer of generic human and veterinary pharmaceuticals. Innovative Irish man, Michael Burke founded the company in 1983, and still leads the company today out of their headquarters in Loughrea, Co. Galway on the west coast of Ireland.
Chanelle Pharma manufactures its own developed products, and also undertakes contract manufacturing of solid dosage forms, liquids and powders, which are packaged, stored, batch released and distributed worldwide. The company is also approved to manufacture controlled medicines. Some of Chanelle Pharma’s products include manufactured anthelmintics, anesthetics and antibiotics that have come to patent.
The multiple award-winning company was named Irish Pharma Company of the Year 2018, making it the first Irish company to win the overall award, which has previously been awarded to global companies. A commitment to research and development is at the heart of the company’s success. Chanelle Pharma holds over 2,500 animal health licenses and over 1,900 product licenses for human health products worldwide, as well as the largest number of registered veterinary licenses of any company in the EU.
Its Loughrea HQ boasts state of the art facilities, including three manufacturing plants, one of which is built to FDA quality standards, and five research and development centers. Chanelle Pharma also has sales offices in the UK and Mumbai, India, and a research and development laboratory in Amman, Jordan.
The company has an enviable reputation for innovation in delivering new generics to market. It now exports from Ireland to over 96 countries worldwide, with key markets in the EU, Australia, New Zealand, Japan, South Africa and the Middle East. With over 96 products in its R&D pipeline, Chanelle Pharma is well positioned to continue to expand into new markets and is currently being audited by the US Food and Drug Administration. Subject to FDA approval of its manufacturing facility, Michael Burke expects to be selling into the US market in the near future.